GEMoaB Monoclonals

GEMoaB Monoclonals is a clinical-stage biotechnology company based in Dresden, Germany, specializing in the development of next-generation immunotherapies for hard-to-treat cancers. The company has pioneered the UniCAR and RevCAR platforms, which utilize switchable 'on/off' mechanisms to enhance the safety and precision of CAR-T cell therapies by using soluble targeting modules. In 2021, GEMoaB was acquired by AvenCell Therapeutics, a joint venture formed by Blackstone Life Sciences, Cellex, and Intellia Therapeutics to integrate GEMoaB's switchable technology with CRISPR-based allogeneic platforms. Its clinical pipeline includes both autologous and allogeneic CAR-T programs targeting CD123 for acute myeloid leukemia, as well as T-cell engaging bispecific antibodies targeting CD33 and PSMA.